Mabylon AG is a Swiss biotechnology company that specializes in the discovery and engineering of novel antibody therapeutics, particularly in the fields of allergy, immunology, and neurology. The company utilizes a sophisticated technology platform that enables the rapid creation of high-quality antibody libraries derived from diverse immune repertoires, focusing on patients with relevant conditions. This approach allows Mabylon to identify and clone natural B-cell-derived antibodies quickly, employing advanced B-cell screening technologies and high-throughput antibody-expression platforms. The resulting monoclonal antibodies are then tested for their therapeutic efficacy in preclinical models, with the aim of developing candidate drugs that exhibit the desired affinity, selectivity, and biological activity.

Mabylon's innovative methodology emphasizes the use of human-derived antibodies, which provide unique insights into human biology and disease mechanisms. In cases where human antibodies are not available for specific targets, the company employs immunization strategies in selected animal species to generate high-quality antibody libraries. This comprehensive approach not only enhances the understanding of allergenic epitopes at a molecular level but also facilitates the identification of therapeutically relevant products. Mabylon's commitment to leveraging cutting-edge technologies in antibody discovery positions it as a key player in the biotechnology landscape, particularly in addressing unmet medical needs in allergy and neurological disorders.

Switzerland

Mabylon AG is a Swiss biotechnology company harnessing the therapeutic potential of naturally occurring human antibodies to treat allergies, neurodegenerative diseases, and inflammation. The firm’s strength is rooted in extensive and successful experiences in both the pharmaceutical and biotech industry, along with a solid academic track record.

Mabylon

Company Details